



NDA 20-782
NDA 21-168/S-004

Abbott Laboratories
Attention: Steven E. Townsend
Associate Director, PPD Regulatory Affairs
200 Abbott Park Road
D491, AP30
Abbott Park, IL 60064-6157

Dear Mr. Townsend:

Please refer to your new drug application (NDA) and supplemental new drug application (sNDA) dated June 26, 2002, received June 27, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Depakote ER (divalproex sodium extended-release) Tablets.

We acknowledge receipt of your submissions dated October 7, 1998, November 18, 1998, August 7, 2002 and November 13, 2002.

We note that your June 26, 2002 submission constituted a complete response to our June 17, 1998 action letter.

These new drug applications provide for the use of Depakote ER Tablets as monotherapy and adjunctive therapy in complex partial seizures in adults and in simple and complex absence seizures in adults and dosing recommendations for converting adult patients from Depakote (divalproex delayed-release tablets) to Depakote ER tablets.

We have completed our review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed, agreed upon labeling text. Accordingly, these applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount ten of the copies on heavy-weight paper or similar material. For

NDA 20-782
NDA 21-168/S-004
Page 2

administrative purposes, designate these **submissions “FPL for approved NDA 20-782/NDA 21-168 S-004.”** Approval of these submissions by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 21-168 for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

FDA's Pediatric Rule [at 21 CFR 314.55/21 CFR 601.27] was challenged in court. On October 17, 2002, the court ruled that FDA did not have the authority to issue the Pediatric Rule and has barred FDA from enforcing it. Although the government decided not to pursue an appeal in the courts, it will work with Congress in an effort to enact legislation requiring pharmaceutical manufacturers to conduct appropriate pediatric clinical trials. In addition, third party interveners have decided to appeal the court's decision striking down the rule. Therefore, we encourage you to submit a pediatric plan that describes development of your product in the pediatric population where it may be used. Please be aware that whether or not this pediatric plan and subsequent submission of pediatric data will be required depends upon passage of legislation or the success of the third party appeal. In any event, we hope you will decide to submit a pediatric plan and conduct the appropriate pediatric studies to provide important information on the safe and effective use of this drug in the relevant pediatric populations.

The pediatric exclusivity provisions of FDAMA as reauthorized by the Best Pharmaceuticals for Children Act are not affected by the court's ruling. Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products. You should refer to the Guidance for Industry on Qualifying for Pediatric Exclusivity (available on our web site at www.fda.gov/cder/pediatric) for details. If you wish to qualify for pediatric exclusivity you should submit a "Proposed Pediatric Study Request". FDA generally does not consider studies submitted to an NDA before issuance of a

NDA 20-782
NDA 21-168/S-004
Page 3

Written Request as responsive to the Written Request. Applicants should obtain a Written Request before submitting pediatric studies to an NDA.

If you have any questions, call Jacqueline H. Ware, Pharm.D., Regulatory Project Manager, at (301) 594-2850.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.

Director

Division of Neuropharmacological Drug Products

Office of Drug Evaluation I

Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Russell Katz
12/20/02 12:13:49 PM